ライフサイエンスコーパス: HSCT

1 uent haemopoietic stem-cell transplantation (HSCT).

2 eic hematopoietic stem cell transplantation (HSCT).

3 logeneic hematopoietic stem cell transplant (HSCT).

4 and hematopoietic stem cell transplantation (HSCT).

5 eic hematopoietic stem cell transplantation (HSCT).

6 ematopoietic stem cell transplantation (allo-HSCT).

7 ing hematopoietic stem cell transplantation (HSCT).

8 ter hematopoietic stem cell transplantation (HSCT).

9 and hematopoietic stem cell transplantation (HSCT).

10 of hematopoietic stem cell transplantation (HSCT).

11 eic hematopoietic stem cell transplantation (HSCT).

12 ematopoietic stem-cell transplantation (allo-HSCT).

13 ore hematopoietic stem cell transplantation (HSCT).

14 ter hematopoietic stem cell transplantation (HSCT).

15 eneic hemopoietic stem cell transplantation (HSCT).

16 eic hematopoietic stem cell transplantation (HSCT).

17 ire hematopoietic stem cell transplantation (HSCT).

18 eic hematopoietic stem cell transplantation (HSCT).

19 eic hematopoietic stem cell transplantation (HSCT).

20 ematopoietic stem cell transplantation (allo-HSCT).

21 ter hematopoietic stem cell transplantation (HSCT).

22 ase is a hematopoietic stem cell transplant (HSCT).

23 ised if relapse occurs beyond 6 months after HSCT.

24 We regularly monitored 67 patients after HSCT.

25 t on growth of malignant lymphoma after allo-HSCT.

26 ed in patients at high risk of relapse after HSCT.

27 cognitive trajectory of patients who undergo HSCT.

28 patients underwent myeloablation followed by HSCT.

29 on of patterns of cellular engraftment after HSCT.

30 rflow decline-free survival after allogeneic HSCT.

31 Six of 14 patients had vasculitis pre-HSCT.

32 ge, and no antibacterial prophylaxis in auto-HSCT.

33 ly relevant, preclinical model of allogeneic HSCT.

34 ty rate at 4 months after auto-HSCT and allo-HSCT.

35 s and antileukemic potential at day 30 after HSCT.

36 of donor-derived NK cells immediately after HSCT.

37 ase must guide decision-making toward timely HSCT.

38 ing virus-specific T cells to patients after HSCT.

39 nd feasibility of CD19 CAR TCM therapy after HSCT.

40 relapsed hematologic cancer after allogeneic HSCT.

41 ation of inhibition capacity 10 months after HSCT.

42 nt GNB was 17.3% in allo-HSCT and 9% in auto-HSCT.

43 ses received 37 VST products before or after HSCT.

44 ed the impact of mutations on the outcome of HSCT.

45 graft-versus-host disease (GVHD) after allo-HSCT.

46 CD8 T cells in the first 3 to 6 months after HSCT.

47 cell repertoire in cancer patients following HSCT.

48 ctory SLE restored C1q production after allo-HSCT.

49 during the most vulnerable period following HSCT.

50 lopment of acute and chronic GVHD after allo-HSCT.

51 lus species hyphal growth was impaired after HSCT.

52 k of diversity of the Treg repertoire before HSCT.

53 of fungal biomarkers in pediatric cancer and HSCT.

54 ights into the biology of HSC recovery after HSCT.

55 ming reset of the Treg compartment following HSCT.

56 to be important for disease remission after HSCT.

57 CD8 T cells, especially 6 to 12 months after HSCT.

58 ity to prevent or treat viral diseases after HSCT.

59 gulatory T-cell (Treg) compartment following HSCT.

60 TFH (cTFH) and B cells in 66 patients after HSCT.

61 al cancer control as planned infusions after HSCT.

62 re and 5 or 9, and 28 days, and 1 year after HSCT.

63 ts from the conventional care group received HSCT.

64 infection by the same microorganism in allo-HSCT.

65 ), CD19(+), and NK-cell output 15 years post-HSCT.

66 th donor-derived CD19 CAR T cells after allo-HSCT.

67 d high transfusion burden are candidates for HSCT.

68 ain major impediments to the success of allo-HSCT.

69 ents or those with comorbidity to receive an HSCT.

70 4 years (range, 17-50 years), underwent Allo-HSCT.

71 el therapeutic target in the setting of allo-HSCT.

72 ME plays a role in development of GVHD after HSCT.

73 e patients with 12 types of PIDs received 26 HSCTs.

74 gister including 3302 patients who underwent HSCT (1007 allogeneic, 2295 autologous) from 1999 throug

75 ember 2014, 28 patients underwent allogeneic HSCT; 13 patients (46%) had CMV viremia, not a statistic

76 eived inotuzumab ozogamicin and proceeded to HSCT, 17 (22%) had sinusoidal obstruction syndrome; five

77 dence interval, 1.45-3.13; P <.001) and auto-HSCT (2.43; 1.22-4.84; P = .01).

78 At 1 year after HSCT, 3-month steroid-free clinical remission was seen i

79 Seven patients underwent autologous HSCT, 6 for MG and 1 for follicular lymphoma with coinci

80 yme activity normalized in those tested post-HSCT (7/7), as early as day +14 (myeloid engraftment).

81 These data indicate that haplo-HSCT after alphabeta T- and B-cell depletion represents

82 luate the outcomes of haploidentical or mMUD HSCT after depleting GvHD-causing T-cell receptor (TCR)

83 Post-HSCT aGVHD developed with an incidence of 57.1% versus 1

84 econdary autoimmune disease after autologous HSCT, all of which resolved or stabilized with treatment

85 gy of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs

86 cal hematopoietic stem cell transplantation (HSCT), allowing safe infusion of unmanipulated T cell-re

87 current hematologic cancers after allogeneic HSCT, although immune-mediated toxic effects and GVHD oc

88 (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GI

89 nce of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT.

90 reased mortality rate at 4 months after auto-HSCT and allo-HSCT.

91 (18)F-FLT) imaging was safe during allogenic HSCT and allowed visualisation of early cellular prolife

92 core have a low chance of cure with standard HSCT and consideration should be given to treating these

93 mature NK cells, starting from day 15 after HSCT and favored by the high levels of interleukin-15 pr

94 All patients who underwent HSCT and had data available at baseline and 1-year follo

95 udied donor-derived CD19 CAR T cells in allo-HSCT and lymphoma models in mice.

96 t trials have produced promising results for HSCT and mesenchymal stromal cell therapy as alternative

97 cantly between myeloablative infusion before HSCT and subclinical HSC recovery (p=0.00031).

98 specific antibodies compared with autologous HSCT and that a highly reactive epitope recognition sign

99 y with myeloma patient sera after allogeneic HSCT and that may be significantly translocated to the c

100 disease who were treated with an allogeneic HSCT and to identify disease- and treatment-related fact

101 y treatment or thereafter (without follow-up HSCT) and after study treatment and subsequent HSCT, for

102 rring during treatment (or follow-up without HSCT) and after treatment and subsequent HSCT-was higher

103 ter hematopoietic stem cell transplantation (HSCT) and can lead to significant morbidity and mortalit

104 eic hematopoietic stem cell transplantation (HSCT) and enteric graft-versus-host disease (GVHD) remai

105 ous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cell therapy have been pro

106 eic hematopoietic stem cell transplantation (HSCT) and to identify novel immunotherapeutic targets.

107 graftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 t

108 ter hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advi

109 patients were randomly assigned to immediate HSCT, and 22 patients were assigned to mobilisation foll

110 , and duration of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, older age, and no ant

111 tebrate viral infections over time following HSCT, and they suggest an unexpected association of pico

112 ly haematopoietic stem cell transplantation (HSCT) approaches for several genetic diseases that can b

113 ease detected on MRI scans at the time of an HSCT are at risk for severe, persistent neurocognitive d

114 eic hematopoietic stem cell transplantation (HSCT) are a major cause of morbidity and mortality.

115 ter hematopoietic stem cell transplantation (HSCT) are rare events.

116 broad antiviral protection to recipients of HSCT as an immediately available off-the-shelf product.

117 ficant barrier against the widespread use of HSCTs as a curative modality.

118 of hematopoietic stem cell transplantation (HSCT) associated with excessive complement activation, l

119 onal therapy in the ASTIC trial were offered HSCT at 1 year and underwent complete assessment for a f

120 born between 1975 and 2009 and who received HSCT at a median age of 7 years (age range, 1.5-18.2 yea

121 have a stable disease course when undergoing HSCT at an early stage with no or only mild gross motor

122 he combined cohort of patients who underwent HSCT at any time during the ASTIC trial programme.

123 Feces collected from adult recipients allo-HSCT at engraftment were analyzed; 16S ribosomal RNA gen

124 L) of IL2RG/JAK3 SCID patients >2 years post-HSCT at our center.

125 nidase, and patients treated with allogeneic HSCT at the onset have improved outcome, suggesting to a

126 All patients with MG treated with autologous HSCT at The Ottawa Hospital were included.

127 lyzed for all boys with cALD who received an HSCT at the University of Minnesota between January 1, 1

128 eic hematopoietic stem cell transplantation (HSCT), at least in younger patients who can tolerate suc

129 eneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 20

130 l of Colorado (CHCO) who received allogeneic HSCT between January 2010 and December 2014.

131 one alkylating agent) and last available pre-HSCT bilirubin concentration of greater than or equal to

132 Allo-HSCT can cure SLE in human C1q deficiency and should be

133 antifying CMV-specific T-cell immunity after HSCT can identify participants at increased risk of clin

134 us haematopoietic stem-cell transplantation (HSCT) compared with mobilisation followed by conventiona

135 d hepatotoxicity, especially after follow-up HSCT, compared with standard care.

136 ategy to control CMV and EBV infection after HSCT, conferring protection in 70%-90% of patients.

137 This ameliorated after HSCT, confirming reset of the Treg compartment following

138 ing hematopoietic stem cell transplantation (HSCT) could assist clinicians in managing CMV-related co

139 roid-free clinical remission at 1 year after HSCT (Crohn's Disease Activity Index [CDAI] <150).

140 Hematopoietic stem cell transplantation (HSCT) cures the T-lymphocyte, B-lymphocyte, and natural

141 a helpful resource for guiding the difficult HSCT decisions in patients with P-CID.

142 Analysis of the HSCT decisions revealed the anticipated heterogeneity, f

143 ecognized as relevant clinical variables for HSCT eligibility.

144 Haemopoietic stem-cell transplantation (HSCT) eradicates host haemopoiesis before venous infusio

145 Herpesviruses infections were uncommon after HSCT, except for CMV and HHV6, which, although relativel

146 During study therapy or follow-up without HSCT, five (3%) patients in the inotuzumab ozogamicin gr

147 least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had available p

148 conditioning regimens can be used safely in HSCT for children with CGD and high-risk clinical featur

149 of 14 patients from 6 countries who received HSCT for DADA2.

150 Among patients undergoing allogeneic HSCT for hematological malignancy, early administration

151 ells infused before and after haploidentical HSCT for high-risk myeloid malignancies.

152 tcomes and shorter survival after allogeneic HSCT for patients with MDS and MDS/AML.

153 outcome of treosulfan-based conditioning in HSCT for pediatric patients with CGD.

154 ng to examine tumor samples collected before HSCT for somatic mutations in 34 recurrently mutated gen

155 The application of autologous HSCT for this and other autoimmune neurologic conditions

156 ter hematopoietic stem cell transplantation (HSCT) for hemophagocytic lymphohistiocytosis (HLH) at th

157 neic haemopoietic stem-cell transplantation (HSCT), for which no approved treatments are available.

158 CT) and after study treatment and subsequent HSCT, for all patients who received at least one dose of

159 variety of approaches, including allogeneic HSCT from CCR5-deficient donors and autologous transplan

160 idney failure after receiving haploidentical HSCT from his father for the treatment of metastatic rha

161 A total of 101 patients underwent allogeneic HSCT from January 2010 to December 2013; 32 (32%) tested

162 ction or hematopoietic stem-cell transplant (HSCT) from 2006 to 2014 was selected.

163 eic hematopoietic stem cell transplantation (HSCT) from an HLA-haploidentical relative (haplo-HSCT) i

164 erral center with expertise in neurology and HSCT, from January 1, 2001, through December 31, 2014, w

165 Nine of the long-term survivors after HSCT had disease progression, while 11 showed stable dis

166 Additionally, HSCT has been a curative therapy for several nonmalignan

167 and immunologic effects of CCR5 blockade in HSCT has not been described.

168 l features of herpesviruses infections after HSCT has not yet been conducted in Brazilian patients, a

169 field of hematopoietic stem cell transplant (HSCT) has made ground-breaking progress in the treatment

170 eic hematopoietic stem cell transplantation (HSCT) has not been prospectively studied.

171 Patients with CD who are eligible for HSCT have typically been failed by most approved therapi

172 increased mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45-

173 Five years after HSCT, he received a preemptive kidney transplant from hi

174 Post-HSCT hematological autoimmunity (cytopenias) was reporte

175 factors at baseline, patients who underwent HSCT (hereafter, transplanted patients) were a priori di

176 ers a differentiation between secondary post-HSCT HLH and HLH related to the genetic defect difficult

177 for controlling CMV and EBV infections after HSCT; however, new practical methods are required to aug

178 sts regarding optimal timing and use of Allo-HSCT in adults, due to lack of experience and previous p

179 ictors of relapse and overall survival after HSCT in both patients with MDS and patients with MDS/AML

180 d limit their undue exposure to the risks of HSCT in first remission.

181 This Review covers the experience with HSCT in HIV infection to date and provides a survey of o

182 We now assess HSCT in patients enrolled in the ASTIC trial using endpo

183 We sought to analyze the results of HSCT in patients with DOCK8 deficiency and report whethe

184 ceptor (TCR) CDR3 diversity before and after HSCT in patients with juvenile idiopathic arthritis and

185 rnative to current conditioning regimens for HSCT in the treatment of non-malignant blood diseases.

186 conditioning and mobilized peripheral blood HSCT in unrelated, fully MHC-matched Mauritian-origin cy

187 ematopoietic stem cell transplantation (Allo-HSCT) in childhood.

188 eic hematopoietic stem cell transplantation (HSCT) in myelodysplastic syndromes (MDS) and chronic mye

189 for hematopoetic stem cell transplantation (HSCT) in patients with severe combined immunodeficiency

190 severe and drug-refractory infections after HSCT, including infections from two viruses (BKV and HHV

191 overall survival in patients with follow-up HSCT (inotuzumab ozogamicin vs standard care) was 1.227

192 CD19(+) cell-depleted haploidentical or mMUD HSCT is a practical and viable alternative for children

193 Cytoreductive therapy prior to HSCT is advised for patients with >/=10% bone marrow mye

194 mmune modulation by DLI strategies or second HSCT is advised if relapse occurs beyond 6 months after

195 patients, for whom the concept of preemptive HSCT is discussed.

196 e role of donor and host Tregs in autologous HSCT is not possible in humans due to the autologous nat

197 hat long-term control of CMV infection after HSCT is primarily mediated through the efficient inducti

198 Allo-HSCT is safe and effective in young adult patients with

199 The objective of HSCT is to immediately shut down the immune response and

200 eic hematopoietic stem cell transplantation (HSCT) is a critically important therapy for hematologica

201 ematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for hematologica

202 ) from an HLA-haploidentical relative (haplo-HSCT) is a suitable option for children with acute leuke

203 Hematopoietic stem cell transplantation (HSCT) is an important therapy for patients with a variet

204 ous hematopoietic stem cell transplantation (HSCT) is increasingly considered for patients with sever

205 ous hematopoietic stem cell transplantation (HSCT) is increasingly used for severe autoimmune and inf

206 eic hematopoietic stem-cell transplantation (HSCT) is unclear.

207 eic hematopoietic stem cell transplantation (HSCT) is used as a therapeutic approach for primary immu

208 Although questions remain concerning HSCT itself (including the need for pretransplant chemot

209 although relatively uncommon, NC after allo-HSCT, may become more frequent due to the improved overa

210 ome was MG disease activity after autologous HSCT measured by frequency of emergency department visit

211 ents occurred between 0.5 and 6.7 years post-HSCT (median DC, 13%; range, 0-30%).

212 These data indicate that HSCT-mediated amelioration of autoimmune disease involve

213 tion of GvHD prophylaxis and next-generation HSCT-mediated therapies for solid organ tolerance, cure

214 sults establish a new preclinical allogeneic HSCT model for evaluation of GvHD prophylaxis and next-g

215 ciated with lymphangiogenesis in murine allo-HSCT models as well as in patient intestinal biopsies.

216 DLL1/DLL4-mediated Notch signaling in murine HSCT models dramatically reduced GVHD and improved graft

217 We found that allogeneic HSCT more efficiently allowed production of myeloma-spec

218 The decision for or against second HSCT must be based on a thorough risk assessment.

219 young (mean age, 22 y) and most had received HSCT ( n = 53).

220 We also observed that post-HSCT neutrophils produced less NETs, which was correlate

221 Treatment of BMT or HSCT neutrophils with phorbol 12-myristate 13-acetate or

222 imary endpoint was survival at day +100 post-HSCT; observed rates equaled 38.2% in the defibrotide gr

223 Neurologic outcomes are better when HSCT occurs at an earlier stage of cALD, yet there is li

224 ous hematopoietic stem cell transplantation (HSCT) of gene-modified cells is an alternative to enzyme

225 Hematopoietic stem cell transplantation (HSCT) offers curative therapy for patients with hemoglob

226 at baseline and 38 patients at 1 year after HSCT (one patient died, one withdrew).

227 who received standard care and proceeded to HSCT, one (3%) had (non-fatal) sinusoidal obstruction sy

228 ients, and the impact of these infections on HSCT outcome remains unclear.

229 Here we show a spectrum of diverse clinical HSCT outcomes including primary and secondary graft fail

230 At 3 months after HSCT, participants who developed CMV disease (n = 8) com

231 antly upregulated in the serum of allogeneic HSCT patients at aGVHD onset compared with non-aGVHD pat

232 ols identified out of 6867 medical charts of HSCT patients by blinded independent reviewers.

233 protocol to diagnose retinitis in pediatric HSCT patients in the early, often asymptomatic stage.

234 ter of CMV retinitis in pediatric allogeneic HSCT patients may suggest a rise in incidence of CMV ret

235 ion in neutrophils isolated from BMT mice or HSCT patients.

236 logeneic hematopoietic stem cell transplant (HSCT) patients are susceptible to pulmonary infections,

237 eic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers.

238 logeneic hematopoietic stem cell transplant (HSCT) population is unknown.

239 eic hematopoietic stem cell transplantation (HSCT), posing as a significant barrier against the wides

240 ug dose intensification and safer allogeneic HSCT procedures, allowing a larger proportion of patient

241 ns, the 5-year probability of survival after HSCT ranged from 0% to 73%.

242 the emergence of genetic variants of CMV in HSCT recipients and correlated these changes with recons

243 ded if pediatric patients had cancer or were HSCT recipients and the intervention was related to the

244 of neutrophils on A fumigatus in allogeneic HSCT recipients at different posttransplantation time po

245 Allogeneic HSCT recipients had an increased risk of BCC, SCC, and M

246 Allogeneic HSCT recipients have an increased risk of BCC, SCC, and

247 trate that while a significant proportion of HSCT recipients may be exposed to multiple genetic varia

248 examined the microbiota composition of allo-HSCT recipients to identify bacterial colonizers that co

249 tional, multicenter, prospective study of 94 HSCT recipients we evaluated CMV-specific T-cell immunit

250 A total of 234 allo-HSCT recipients were studied; postengraftment CDI develo

251 The detection of hMPV-specific T cells in HSCT recipients who endogenously controlled active infec

252 t and improved immune reconstitution in allo-HSCT recipients with aGVHD.

253 Among 297 allogeneic HSCT recipients, 85 (28.7%) were HBsAg-negative, anti-HB

254 e study cohort included 452 adult-allogeneic HSCT recipients, transplanted from 1997 to 2012.

255 peripheral blood samples from 98 allogeneic HSCT recipients.

256 ion as part of a prospective study of TMA in HSCT recipients.

257 ancer in hematopoietic stem-cell transplant (HSCT) recipients has not been extensively studied.

258 logeneic hematopoietic stem cell transplant (HSCT) recipients, in whom it can cause significant morbi

259 tions in hematopoietic stem cell transplant (HSCT) recipients.

260 logeneic hematopoietic stem cell transplant (HSCT) recipients.

261 fety outcomes included all severe autologous HSCT-related complications.

262 s-host disease (GVHD) and relapse after allo-HSCT remain major impediments to the success of allo-HSC

263 eic hematopoietic stem cell transplantation (HSCT) remains the only treatment option for several seve

264 HSCT represents a curative therapy for patients with MYS

265 Hematopoietic stem cell transplantation (HSCT) represents a potential definitive treatment.

266 Optimal timing of HSCT requires careful evaluation of the available effect

267 eic hematopoietic stem cell transplantation (HSCT) requires the balanced reconstitution of donor-deri

268 of conventional therapy in Crohn's disease, HSCT resulted in clinical and endoscopic benefit, althou

269 apid MLD progression 1.5 and 8.6 years after HSCT, resulting in a 5-year survival of 79% (19 of 24).

270 Autologous HSCT results in long-term symptom- and treatment-free re

271 extended indication of curative treatment by HSCT should be considered.

272 allogeneic nonmyeloablative HSC transplants (HSCTs), stable mixed chimerism is sufficient to reverse

273 yme replacement therapy (ERT) and allogeneic HSCT that has shown clinical benefit for adenosine deami

274 After allogeneic HSCT, the respective 12-month rates were 53% and 63%.

275 d significantly advance critical, lifesaving HSCT therapies.

276 Autologous HSCT using genetically corrected cells would avoid the r

277 longitudinal gut virome in 44 recipients of HSCT using metagenomics.

278 eic hematopoietic stem cell transplantation (HSCT), viral infections are still a major complication d

279 The median follow-up after HSCT was 7.5 years (range, 3.0-19.7 years).

280 The median age at HSCT was 7.5 years.

281 In conclusion, in 14 patients, HSCT was an effective and definitive treatment of DADA2.

282 Indication for HSCT was bone marrow dysfunction or immunodeficiency.

283 A second HSCT was performed in 18 patients (median, DC 4%; range,

284 eic hematopoietic stem cell transplantation (HSCT) was monitored.

285 out HSCT) and after treatment and subsequent HSCT-was higher in the inotuzumab ozogamicin group (22 [

286 (SD) ages at MG diagnosis and at autologous HSCT were 37 (11) and 44 (10) years, respectively.

287 uction syndrome; five events after follow-up HSCT were fatal.

288 Patients after HSCT were more likely to have a stable disease course wh

289 h undetectable HBV DNA undergoing allogeneic HSCT were prospectively monitored every 4 weeks.

290 of hematopoietic stem cell transplantation (HSCT) were not influenced by mutational status.

291 ematopoietic stem cell transplantation (allo-HSCT), who receive intensive treatments that significant

292 eic hematopoietic stem-cell transplantation (HSCT) will require efforts to decrease treatment-related

293 ction of early subclinical engraftment after HSCT with (18)F-FLT PET or CT.

294 the same donor after previous haploidentical HSCT with a corticosteroid taper alone.

295 nsequence, in an extended series of 99 haplo-HSCT with PT-Cy, we found no significant difference in p

296 nrolled on a trial of reduced-intensity allo-HSCT with standard GVHD prophylaxis plus maraviroc to a

297 ts were successfully treated with allogeneic HSCT with sustained reconstitution of hematopoietic defe

298 gh rate of HBV reactivation after allogeneic HSCT, with determinants of HBV reactivation including ag

299 vivo-expanded NK cells after haploidentical HSCT without adverse effects, increased GVHD, or higher

300 HSCT would be greatly improved if patient-specific hemat